• 1
    United Nations Programme on HIV/AIDS and World Health Organization (UNAIDS/WHO). Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections. Mexico, 2006. Available from:[Accessed May 5, 2008.
  • 2
    Centro Nacional para la Prevención y el Control del VIH/SIDA. AIDS in numbers. Available from:[Accessed August 12, 2008.
  • 3
    Bravo-Garcia E, Magis-Rodriquez C, Saavedra J. New estimates in Mexico: more than 180 000 people living with HIV. Abstract CDC0411. XVI International AIDS Conference; 2006 August 13–18; Toronto, ON, Canada.
  • 4
    World Health Organization (WHO). HIV prevalence among adults aged ≥15 years (per 100 000 population). WHO Statistical Information System page. Available from:[Accessed May 5, 2008.
  • 5
    Bautista-Arredondo S, Mane A, Bertozzi SM. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS 2006;20:1019.
  • 6
    World Health Organization (WHO). Significant growth in access to HIV treatment in 2006: More efforts needed for universal access to services. Media Centre page. 2007. Available from:[Accessed May 5, 2008.
  • 7
    Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:142941.
  • 8
    Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. Abstract of poster presentation 792. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 2008; Boston, MA, USA.
  • 9
    Pfizer Inc. Selzentry (maraviroc). Prescribing information (US Label). 2007.
  • 10
    Kuhne FC, Chancellor J, Mollon P, et al. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clin Trials 2010;11:8099.
  • 11
    Henry K, Tebas P, Lane C. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA 2006;296:15235.
  • 12
    Multicenter AIDS Cohort Study (MACS) Public Data Set: Release P04. 1995. Springfield, VA: National Technical Information Service.
  • 13
    Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158:68794.
  • 14
    D'Arminio MA, Sabin CA, Phillips A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005;165:41623.
  • 15
    Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:94654.
  • 16
    Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistent HIV infection in North and South America. N Engl J Med 2003;348:217585.
  • 17
    Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:218695.
  • 18
    Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006;42:8707.
  • 19
    Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001;345:398407.
  • 20
    Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000;14:F8393.
  • 21
    Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006;296:76981.
  • 22
    Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:72533.
  • 23
    Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:2017.
  • 24
    US Department of Health and Human Services. U.S. Public Health Service and the Infectious Diseases Society of America. Guidelines for the Prevention of Opportunistic Infections Among HIV-Infected Persons—2002. June 14, 2002. Available from:[Accessed April 18, 2008.
  • 25
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. 2008;1128. Available from:[Accessed April 18, 2008.
  • 26
    Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002;22:2738.
  • 27
    Paltiel AD, Scharfstein JA, Seage GR, III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998;18(Suppl.):S93105.
  • 28
    Zbrozek AS, Cantor SB, Cardenas MP, Hill DP, Jr. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 1994;51:155563.
  • 29
    Consejo Nacional de Población. Mexico en Cifras: Indicadores Demográficos Básicos. Available from:[Accessed May 5, 2008.
  • 30
    Consejo de Salubridad General. Guía para la conducción de estudios de evaluación económica para la actualización del Cuadro Básico de Insumos del Sector Salud en México. Dirección General Adjunta de Priorización. Comisión interinstitucional del Cuadro Básico de Insumos del Sector Salud. 2008. Available from:[Accessed June 20, 2010.
  • 31
    Diario Oficial de la Federación. Costos Unitarios de Atención Médica. Instituto Mexicano del Seguro Social (IMSS). Martes 9 de Marzo de 2004.
  • 32
    OANDA the Currency Site. FX history: historical currency exchange rates. Available from:[Accessed July 18, 2008.
  • 33
    Instituto Mexicano del Seguro Social (IMSS). Portal de Transparencia. Available from:[Accessed May 5, 2008.
  • 34
    Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med 1999;131:1948.
  • 35
    Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004;5:294304.
  • 36
    Cordova-VillalobosJA, Ponce de León-RosalesS, ValdespinoJL, Authors, eds. 25 años de SIDA en México. Logros, desaciertos y retos. Primera edición. Cuernavaca, Mexico: Instituto Nacional de Salud Pública, 2008.
  • 37
    Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:5439.
  • 38
    Fiscus SA, Hughes MD, Lathey JL, et al. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 174 Team. J Infect Dis 1998;177:525633.
  • 39
    Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 2005;39:6977.
  • 40
    Grosse SD. Assessing cost-effectiveness in health care: history of the $50,000 per QALY threshold. Expert Rev Pharmacoeconomics Outcomes Res 2008;8:16578.
  • 41
    PNUD. Informe sobre desarrollo humano 2007–2008. La lucha contra el cambio climático: Solidaridad frente a un mundo dividido. New York: Grupo Mundi-Prensa, 2007.
  • 42
    Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;1:40412.
  • 43
    Raffi F. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. Med Mal Infect 2004;34:817.
  • 44
    Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006;44:9907.